Similar articles

• Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.

  Griñó JM, Castelao AM, Serón D, Gonzalez C, Galceran JM, Gil-Vernet S, Andrés E, Bover J, Torras J, Alsina J. Griñó JM, et al. Transplant Proc. 1992 Feb;24(1):39-41. Transplant Proc. 1992. PMID: 1539329 Clinical Trial. No abstract available.
• Late acute rejection in renal transplant recipients: response to steroid treatment.

  Prieto C, Pulido F, Rodríguez-Paternina E, Algranati C, Bello I, Farias J, G-Millet V. Prieto C, et al. Transplant Proc. 1992 Feb;24(1):35-6. Transplant Proc. 1992. PMID: 1539312 Clinical Trial. No abstract available.
• Cytokine-release syndrome: differences between high and low doses of OKT3.

  Norman DJ, Kimball JA, Barry JM. Norman DJ, et al. Transplant Proc. 1993 Apr;25(2 Suppl 1):35-8. Transplant Proc. 1993. PMID: 8465420 Clinical Trial. No abstract available.
• Antibody induction therapy in pancreas transplantation.

  Gruessner RW. Gruessner RW. Transplant Proc. 1998 Jun;30(4):1556-9. doi: 10.1016/s0041-1345(98)00356-x. Transplant Proc. 1998. PMID: 9636632 Review. No abstract available.
• Renal transplant immunity and immunosuppression.

  McEnery PT, Fine R, Ascher N, Ettenger R, Conley S, Friedman J, Tejani A. McEnery PT, et al. Am J Kidney Dis. 1986 Apr;7(4):312-7. doi: 10.1016/s0272-6386(86)80073-7. Am J Kidney Dis. 1986. PMID: 3515911 Review. No abstract available.